Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that a partial clinical hold has been placed on the Company's Phase Ib/II clinical trial of clivatuzumab tetraxetan in patients with advanced pancreatic cancer, due to the administration of an incorrect dose to a patient enrolled at one of its trial sites.
Read the full article and the disclaimer at: http://pennytobuck.com/?p=17245
(IMMU, MJGCF.PK, FXEN, APWC) Stocks in Focus by PennyToBuck.com
September 28th, 2011 at 09:57 am